关注并星标CPHI制药在线跨国药企巨头强生交出一份“冰火交织”的半年报!7月16日公布的业绩显示:2025H1总营收456亿美元,肿瘤板块以21.1%增速逆势突围,达雷妥尤单抗独揽68亿美元,CAR-T疗法Carvykti暴增135%冲击年度20亿目标。但自免领域受生物类似药冲击下滑14%,昔日王牌乌司奴单抗缩水近四成。在创新药与收购双轮驱动下,强生正加速重构业务版图。肿瘤三驾马车拉动119亿...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.